## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549	

OMB APPROVAL							
OMB Number: 3235-028							
Estimated average burden							
hours per response.	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person GARCEAU ROGER				2. Issuer Name and Ticker or Trading Symbol Entera Bio Ltd. [ ENTX ]							(Che	Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner				
(Last)	(F	First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 01/01/2024							Officer ( below)	give title	Other (sbelow)	specify	
KIRYAT HADASSAH, MINRAV BUILDING, 5TH FLOOR					4. If Amendment, Date of Original Filed (Month/Day/Year)						Line)	6. Individual or Joint/Group Filing (Check Applicable .ine)  X Form filed by One Reporting Person				
(Street) JERUSALEM L3 9112002				Data 40h 5 4(a) Tanana Kanada Kiri								Form filed by More than One Reporting Person				
(City)	(5	State)	(Zip)		Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											
1. Title of Security (Instr. 3)  2. Transa Date			2. Transact	action 2A. Deemed Execution Date,		3. Transact	Transaction Disposed Of (D) (II Code (Instr.		f, or Beneficially ( les Acquired (A) or Of (D) (Instr. 3, 4 and 5)		5. Amount of		Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	/ Amo	Amount (A) or (D)		Price	Transaction (Instr. 3 ar			(IIISU. 4)	
			Table II - D					quired, Dis s, options					wned			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yes	Code	ransaction Derivative Expode (Instr. Securities (Mo		Expiration D	5. Date Exercisable and Expiration Date Month/Day/Year)  7. Title and Amo Securities Under Derivative Secur (Instr. 3 and 4)		Inderlying Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expirati Date	ion	Title	Amount or Number of Shares		(Instr. 4)	5)	
Stock Option (right to buy)	\$0.6	01/01/2024		A		108,333		(1)	01/01/20	034	Ordinary Shares, par value NIS 0.0000769 per share	108,333	\$0	108,333	D	

## Explanation of Responses:

1. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2024.

/s/ Dana Yaacov-Garbeli, Attorney-in-fact

01/03/2024

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.